These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?The Motley Fool • 10/12/26
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?The Motley Fool • 10/10/26
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up24/7 Wall Street • 10/09/26
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?The Motley Fool • 10/08/26
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersInvestors Business Daily • 10/06/26
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher24/7 Wall Street • 10/06/26
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up24/7 Wall Street • 10/05/26
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips24/7 Wall Street • 10/05/26
After Moderna's 'Outsized Run,' It May Be Time For This Bearish MoveInvestors Business Daily • 10/01/26
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water24/7 Wall Street • 10/01/26
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This YearInvestopedia • 09/30/26